ARCTURUS THERAPEUTICS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $500.00K, a 84.85% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.30M, a 23.26% decline from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $4.30M, a 168.75% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.60M, a 55.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-03-03 |
| 2024-12-31 | $3.30M 10-K · filed 2026-03-03 |
| 2023-12-31 | $4.30M 10-K · filed 2026-03-03 |
| 2022-12-31 | $1.60M 10-K · filed 2025-03-06 |
| 2021-12-31 | $3.60M 10-K · filed 2024-03-14 |
| 2020-12-31 | $20.20M 10-K · filed 2022-03-01 |
| 2019-12-31 | $100.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |